About Us
About Combinent Biomedical Systems
Combinent Biomedical Systems focuses on the transvaginal delivery of drugs targeting women’s reproductive endocrinology disorders. Our vaginal rings are made out of ethylene-vinyl-acetate; a polymer which is widely used in medical products including FDA approved vaginal rings. We use a matrix design in which the drug and polymer are interspersed throughout the entire ring. This design allows for the delivery of hydrophobic and hydrophilic molecules as well as proteins and other large molecules. We have also designed segmented rings where each segment contains a different drug, uniquely formulated for its optimal pharmacokinetics, but with the ability to be delivered in a single device.
We are targeting women’s reproductive endocrinology disorders initially. Follow-on applications include diabetes, obesity, and infectious disease. Combinent Biomedical Systems has raised a total of $5.12M over 6 funding rounds: 4 Early-Stage and 2 Debt rounds.
Multi-Segmented Vaginal Ring with Trans-Vaginal Delivery
- Drug standard = subcutaneous delivery (IV or IM)
- Alternate Routes of Delivery = Oral, Pulmonary, Nasal, Buccal, Transdermal, Vaginal, Ocular, Aural
- Vaginal Advantages over Alt. Routes of Delivery
- Permeability .5 - 20x
- Bioavailability 20 - 80x (30-85% sub q)
- Contact Time -w/o adhesive 15 - 40x with adhesive 4 - 7x
- Half-life 1 - 2x